Brief: Eckert & Ziegler Says Pentixapharm Announces First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)

Eckert & Ziegler SE

22/11/2023 15:12

Nov 22 (Reuters) - ECKERT & ZIEGLER STRAHLEN UND
MEDIZINTECHNIK AG  EUZG.DE :
    * PENTIXAPHARM AG TODAY HAS ANNOUNCED THAT A FIRST PATIENT
HAS
BEEN TREATED IN A DOSE-FINDING CLINICAL PHASE I/II STUDY WITH
YTTRIUM (90Y) ANDITIXAFORTIDE (PENTIXATHER) AT UNIVERSITY
HOSPITAL IN ESSEN, GERMANY
    * BEFORE TREATMENT, PATIENTS WILL BE SCREENED WITH
GALLIUM-68
(68GA)-BASED PENTIXAFOR TO CONFIRM PRESENCE OF CXCR-4 RECEPTORS
    * IF PET SCAN TURNS OUT TO BE POSITIVE, PENTIXATHER WILL BE
GIVEN
IN VARIOUS DOSES TO DIFFERENT DOSE GROUP (IN TOTAL 9 TO 15
PATIENTS)
    * ENROLLMENT IS PLANNED TO LAST 12 MONTHS
    * PENTIXATHER IS TARGETING CXCR-4 CYTOKINE RECEPTOR WHICH IS
WIDELY EXPRESSED IN DIFFERENT CANCER INDICATIONS

Source text for Eikon:  ID:nEQ1yLtv8a 
Further company coverage:  EUZG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))